MapLight Therapeutics, Inc. (MPLT) fair value analysis
Nasdaq · Updated 2026-10-19
MPLT price how computed
Valuation status
No fair-value estimate yetMPLT has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for MPLT yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $7.70
- Sector
- Healthcare
- 12-month range
- $7.70–$39.80
- Market cap
- $407M
- From 52-week high
- -80.7%
- Shares outstanding
- 52.8M
- Rank in Healthcare by quality score
- #253 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases of the retina and central nervous system. The company is headquartered in the United States and operates as a publicly traded entity on the Nasdaq stock exchange.
MPLT currently ranks #253 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $407M
- P/E (trailing)
- n/m
- EPS (TTM)
- $-42.31
- Debt / equity
- 0.01
- Shares outstanding
- 52.8M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 16 · oversold
- 50-day average
- $11.21
- 200-day average
- $20.99
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-12-03
- Last 5 quarters vs consensus
- 1 beat, 4 missed
- Quarter by quarter
- 2026-06 ▲ beat (+5.7%)
2026-03 ▼ miss (-22.9%)
2025-12 ▼ miss (-197.6%)
2025-09 ▼ miss (-2061.6%)
2025-06 ▼ miss
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 12 buy · 2 hold · 0 sell (14 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $26.5
- Target vs last price
- +244.2%
What our data shows for MPLT
- Shares are trading in the lower third of their 12-month price range of $7.70–$39.80.
- The 14-day relative strength index sits at an oversold 16.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- MPLT's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the MPLT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is MPLT stock undervalued?
TickrTrends has no fair-value estimate for MPLT yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is MPLT's TickrTrends verdict?
MPLT is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does MPLT compare to other Healthcare stocks?
MPLT ranks #253 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is MPLT overbought or oversold?
MPLT's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does MPLT report earnings next?
MPLT's next earnings report is scheduled for 2026-12-03, per the published earnings calendar.
Does MPLT usually beat earnings estimates?
Over its last 5 reported quarters MPLT beat the consensus estimate 1 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MPLT?
Of 14 analysts covering MPLT, 12 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $26.5 (+244.2% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.